Glimric M1 Forte Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 1000mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet and exercise alone. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which enhances glucose uptake and utilization. The extended-release formulation of Glimric M1 Forte allows for a gradual release of metformin, improving gastrointestinal tolerability and providing sustained glycemic control over 24 hours. This combination therapy targets multiple pathophysiological defects of type 2 diabetes, offering improved efficacy compared to monotherapy. It is recommended to be taken once daily with meals to minimize gastrointestinal side effects. Glimric M1 Forte should be used cautiously in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and lactic acid levels is advised during therapy. This medication should be prescribed and used under medical supervision to optimize glycemic control and minimize adverse effects.